{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:09:07Z","timestamp":1793563747967,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,9]]},"DOI":"10.7759\/cureus.23993","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T22:25:40Z","timestamp":1649543140000},"source":"Crossref","is-referenced-by-count":3,"title":["Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era"],"prefix":"10.7759","author":[{"given":"Selim","family":"Jennane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"Ababou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariyam","family":"El Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Ait Sahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El Mehdi","family":"Mahtat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"El Maaroufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahim","family":"Doudouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Doghmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg020","article-title":"Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours","volume":"14","author":"O'Sullivan JM","year":"2003","unstructured":"O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003, 14:91-6. 10.1093\/annonc\/mdg020","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma","volume":"23","author":"Martin WG","year":"2005","unstructured":"Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005, 23:7614-20. 10.1200\/JCO.2005.02.7243","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1663419","article-title":"Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era","volume":"61","author":"Taparra K","year":"2020","unstructured":"Taparra K, Liu H, Polley MY, Ristow K, Habermann TM, Ansell SM. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. Leuk Lymphoma. 2020, 61:298-308. 10.1080\/10428194.2019.1663419","journal-title":"Leuk Lymphoma"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1311","article-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease","volume":"104","author":"Straus DJ","year":"2004","unstructured":"Straus DJ, Portlock CS, Qin J, et al.. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004, 104:3483-9. 10.1182\/blood-2004-04-1311","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.8138","article-title":"Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 Trial","volume":"33","author":"Advani RH","year":"2015","unstructured":"Advani RH, Hong F, Fisher RI, et al.. Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015, 33:1936-42. 10.1200\/JCO.2014.57.8138","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing KH","year":"2014","unstructured":"Xing KH, Connors JM, Lai A, et al.. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood. 2014, 123:3567-73. 10.1182\/blood-2013-12-541078","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0300-x","article-title":"Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK","volume":"119","author":"Watson RA","year":"2018","unstructured":"Watson RA, De La Pe\u00f1a H, Tsakok MT, et al.. Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. Br J Cancer. 2018, 119:1044-51. 10.1038\/s41416-018-0300-x","journal-title":"Br J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.5.779","article-title":"Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group","volume":"8","author":"McKeage MJ","year":"1990","unstructured":"McKeage MJ, Evans BD, Atkinson C, Perez D, Forgeson GV, Dady PJ. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. J Clin Oncol. 1990, 8:779-83. 10.1200\/JCO.1990.8.5.779","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000502374","article-title":"Can we predict bleomycin toxicity with PET-CT?","volume":"142","author":"Beyhan Sagmen S","year":"2019","unstructured":"Beyhan Sagmen S, Comert S, Turan Erkek E, et al.. Can we predict bleomycin toxicity with PET-CT?. Acta Haematol. 2019, 142:171-5. 10.1159\/000502374","journal-title":"Acta Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.1.47.47","article-title":"Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987","volume":"73","author":"Tubiana M","year":"1989","unstructured":"Tubiana M, Henry-Amar M, Carde P, et al.. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989, 73:47-56. 10.1182\/blood.V73.1.47.47","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever D","year":"1998","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998, 339:1506-14. 10.1056\/NEJM199811193392104","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes A","year":"2013","unstructured":"Younes A, Connors JM, Park SI, et al.. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013, 14:1348-56. 10.1016\/S1470-2045(13)70501-1","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"128","author":"Kumar A","year":"2016","unstructured":"Kumar A, Casulo C, Yahalom J, et al.. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016, 128:1458-64. 10.1182\/blood-2016-03-703470","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-019-01010-4","article-title":"Acute lung injury: IL-17A-mediated inflammatory Pathway and its regulation by curcumin","volume":"42","author":"Gouda MM","year":"2019","unstructured":"Gouda MM, Bhandary YP. Acute lung injury: IL-17A-mediated inflammatory Pathway and its regulation by curcumin. Inflammation. 2019, 42:1160-9. 10.1007\/s10753-019-01010-4","journal-title":"Inflammation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson P","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, et al.. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016, 374:2419-29. 10.1056\/NEJMoa1510093","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll B","year":"2016","unstructured":"B\u00f6ll B, Goergen H, Behringer K, et al.. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016, 127:2189-92. 10.1182\/blood-2015-11-681064","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors JM","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, et al.. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018, 378:331-44. 10.1056\/NEJMoa1708984","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.628","article-title":"Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours","volume":"78","author":"Simpson AB","year":"1998","unstructured":"Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer. 1998, 78:1061-6. 10.1038\/bjc.1998.628","journal-title":"Br J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8451","article-title":"Pulmonary function in patients with germ cell cancer treated with bleomycin, etoposide, and cisplatin","volume":"34","author":"Lauritsen J","year":"2016","unstructured":"Lauritsen J, Kier MG, Bandak M, Mortensen MS, Thomsen FB, Mortensen J, Daugaard G. Pulmonary function in patients with germ cell cancer treated with bleomycin, etoposide, and cisplatin. J Clin Oncol. 2016, 34:1492-9. 10.1200\/JCO.2015.64.8451","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.2.617","article-title":"Bleomycin-induced pneumonitis","volume":"120","author":"Sleijfer S","year":"2001","unstructured":"Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001, 120:617-24. 10.1378\/chest.120.2.617","journal-title":"Chest"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363150-00004","article-title":"Long-term complications of chemotherapy for germ cell tumours","volume":"63","author":"Chaudhary UB","year":"2003","unstructured":"Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs. 2003, 63:1565-77. 10.2165\/00003495-200363150-00004","journal-title":"Drugs"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-198803000-00006","article-title":"Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide","volume":"295","author":"Lower EE","year":"1988","unstructured":"Lower EE, Strohofer S, Baughman RP. Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am J Med Sci. 1988, 295:193-7. 10.1097\/00000441-198803000-00006","journal-title":"Am J Med Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1297","article-title":"Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease","volume":"14","author":"Hirsch A","year":"1996","unstructured":"Hirsch A, Vander Els N, Straus DJ, Gomez EG, Leung D, Portlock CS, Yahalom J. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol. 1996, 14:1297-305. 10.1200\/JCO.1996.14.4.1297","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas A","year":"2015","unstructured":"Stamatoullas A, Brice P, Bouabdallah R, et al.. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015, 170:179-84. 10.1111\/bjh.13419","journal-title":"Br J Haematol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/28.9.546","article-title":"Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity","volume":"28","author":"Kawai K","year":"1998","unstructured":"Kawai K, Hinotsu S, Tomobe M, Akaza H. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Jpn J Clin Oncol. 1998, 28:546-50. 10.1093\/jjco\/28.9.546","journal-title":"Jpn J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-1032-z","article-title":"Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma","volume":"90","author":"Ngeow J","year":"2011","unstructured":"Ngeow J, Tan IB, Kanesvaran R, Tan HC, Tao M, Quek R, Lim ST. Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma. Ann Hematol. 2011, 90:67-72. 10.1007\/s00277-010-1032-z","journal-title":"Ann Hematol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/BF00735929","article-title":"Pulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapy","volume":"32","author":"Ngan HY","year":"1993","unstructured":"Ngan HY, Liang RH, Lam WK, Chan TK. Pulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapy. Cancer Chemother Pharmacol. 1993, 32:407-9. 10.1007\/BF00735929","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197607)38:1<8::aid-cncr2820380103>3.0.co;2-4","article-title":"Phase II evaluation of bleomycin. A Southwest oncology Group study","volume":"38","author":"Haas CD","year":"1976","unstructured":"Haas CD, Coltman CA Jr, Gottlieb JA, et al.. Phase II evaluation of bleomycin. A Southwest oncology Group study. Cancer. 1976, 38:8-12. 10.1002\/1097-0142(197607)38:1&lt;8::aid-cncr2820380103&gt;3.0.co;2-4","journal-title":"Cancer"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8461","article-title":"Randomized trial comparing bleomycin\/etoposide\/cisplatin with alternating cisplatin\/cyclophosphamide\/doxorubicin and vinblastine\/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP","volume":"26","author":"Culine S","year":"2008","unstructured":"Culine S, Kramar A, Th\u00e9odore C, et al.. Randomized trial comparing bleomycin\/etoposide\/cisplatin with alternating cisplatin\/cyclophosphamide\/doxorubicin and vinblastine\/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol. 2008, 26:421-7. 10.1200\/JCO.2007.13.8461","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.6.1629","article-title":"Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council","volume":"19","author":"de Wit R","year":"2001","unstructured":"de Wit R, Roberts JT, Wilkinson PM, et al.. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001, 19:1629-40. 10.1200\/JCO.2001.19.6.1629","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1837","article-title":"Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group","volume":"15","author":"de Wit R","year":"1997","unstructured":"de Wit R, Stoter G, Kaye SB, et al.. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997, 15:1837-43. 10.1200\/JCO.1997.15.5.1837","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.470","article-title":"Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial","volume":"13","author":"Loehrer PJ Sr","year":"1995","unstructured":"Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995, 13:470-6. 10.1200\/JCO.1995.13.2.470","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n","article-title":"A clinical review of bleomycin--a new antineoplastic agent","volume":"31","author":"Blum RH","year":"1973","unstructured":"Blum RH, Carter SK, Agre K. A clinical review of bleomycin--a new antineoplastic agent. Cancer. 1973, 31:903-14. 10.1002\/1097-0142(197304)31:4&lt;903::aid-cncr2820310422&gt;3.0.co;2-n","journal-title":"Cancer"},{"key":"ref34","article-title":"Prospective study of the pulmonary toxicity of continuously infused bleomycin","volume":"65","author":"Cooper KR","year":"1981","unstructured":"Cooper KR, Hong WK. Prospective study of the pulmonary toxicity of continuously infused bleomycin. Cancer Treat Rep. 1981, 65:419-25.","journal-title":"Cancer Treat Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218804293","article-title":"Risk of pulmonary toxicity of bleomycin and filgrastim","volume":"25","author":"Laprise-Lachance M","year":"2019","unstructured":"Laprise-Lachance M, Lemieux P, Gr\u00e9goire JP. Risk of pulmonary toxicity of bleomycin and filgrastim. J Oncol Pharm Pract. 2019, 25:1638-44. 10.1177\/1078155218804293","journal-title":"J Oncol Pharm Pract"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1515939","article-title":"The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor","volume":"60","author":"Andersen MD","year":"2019","unstructured":"Andersen MD, Kamper P, d'Amore A, Clausen M, Bentzen H, d'Amore F. The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor. Leuk Lymphoma. 2019, 60:927-33. 10.1080\/10428194.2018.1515939","journal-title":"Leuk Lymphoma"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.05.055","article-title":"Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group","volume":"70","author":"Macann A","year":"2008","unstructured":"Macann A, Bredenfeld H, M\u00fcller RP, Diehl V, Engert A, Eich HT. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group. Int J Radiat Oncol Biol Phys. 2008, 70:161-5. 10.1016\/j.ijrobp.2007.05.055","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199004000-00009","article-title":"Increased pulmonary toxicity with bleomycin and cisplatin chemotherapy combinations","volume":"13","author":"Rabinowits M","year":"1990","unstructured":"Rabinowits M, Souhami L, Gil RA, Andrade CA, Paiva HC. Increased pulmonary toxicity with bleomycin and cisplatin chemotherapy combinations. Am J Clin Oncol. 1990, 13:132-8. 10.1097\/00000421-199004000-00009","journal-title":"Am J Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21808","article-title":"Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project","volume":"106","author":"Belknap SM","year":"2006","unstructured":"Belknap SM, Kuzel TM, Yarnold PR, Slimack N, Lyons EA, Raisch DW, Bennett CL. Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer. 2006, 106:2051-7. 10.1002\/cncr.21808","journal-title":"Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1159\/000101517","article-title":"Increased pulmonary FDG uptake in bleomycin-associated pneumonitis","volume":"30","author":"von Rohr L","year":"2007","unstructured":"von Rohr L, Klaeser B, Joerger M, Kluckert T, Cerny T, Gillessen S. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie. 2007, 30:320-3. 10.1159\/000101517","journal-title":"Onkologie"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11856","article-title":"FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity","volume":"92","author":"Buchler T","year":"2007","unstructured":"Buchler T, Bomanji J, Lee SM. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity. Haematologica. 2007, 92:e120-1. 10.3324\/haematol.11856","journal-title":"Haematologica"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-008-0183-7","article-title":"Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma","volume":"22","author":"Yamane T","year":"2008","unstructured":"Yamane T, Daimaru O, Ito S, et al.. Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma. Ann Nucl Med. 2008, 22:719-22. 10.1007\/s12149-008-0183-7","journal-title":"Ann Nucl Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1236379","article-title":"Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma","volume":"58","author":"Falay O","year":"2017","unstructured":"Falay O, \u00d6zt\u00fcrk E, B\u00f6l\u00fckba\u015f\u0131 Y, et al.. Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma. Leuk Lymphoma. 2017, 58:1114-22. 10.1080\/10428194.2016.1236379","journal-title":"Leuk Lymphoma"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/92063-bleomycin-induced-lung-toxicity-in-hodgkins-lymphoma-risk-factors-in-the-positron-emission-tomography-era","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:24Z","timestamp":1707507924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/92063-bleomycin-induced-lung-toxicity-in-hodgkins-lymphoma-risk-factors-in-the-positron-emission-tomography-era"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.23993","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,9]]}}}